INS and obesity disorder: Prolonged GPx-1 activation in animal models may disrupt insulin signaling pathways (40, 41), and GPx-1 overexpression has been associated with obesity and insulin resistance in experimental settings (42), whereas its reduction tends to mitigate these effects (43).